Analyst Ratings For Aclaris Therapeutics (NASDAQ:ACRS)
Today, Leerink Swann lowered its price target on Aclaris Therapeutics (NASDAQ:ACRS) to $54.00 per share.
Some recent analyst ratings include
- 3/12/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 2/8/2018-Guggenheim initiated coverage with a Buy rating.
- 9/8/2017-JMP Securities Reiterated Rating of Outperform.
- 7/31/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics (NASDAQ:ACRS) has insider ownership of 16.30% and institutional ownership of 92.40%.
- On 8/16/2017 Andrew N Schiff, Director, bought 108,601 with an average share price of $23.02 per share and the total transaction amounting to $2,499,995.02.
- On 3/2/2017 Ventures Fund Vii L.P. Vivo, Major Shareholder, sold 425,000 with an average share price of $30.82 per share and the total transaction amounting to $13,098,500.00.
- On 1/10/2017 Anand Mehra, Director, sold 750,000 with an average share price of $28.25 per share and the total transaction amounting to $21,187,500.00.
- On 11/18/2016 Ventures Fund Vii L.P. Vivo, Major Shareholder, sold 907,828 with an average share price of $23.03 per share and the total transaction amounting to $20,907,278.84.
- On 10/26/2016 Kamil Ali-Jackson, Insider, sold 3,912 with an average share price of $21.83 per share and the total transaction amounting to $85,398.96.
- On 9/28/2016 Kamil Ali-Jackson, Insider, sold 1,841 with an average share price of $24.66 per share and the total transaction amounting to $45,399.06.
- On 9/16/2016 Ra Capital Management, Llc, Major Shareholder, sold 525,550 with an average share price of $24.19 per share and the total transaction amounting to $12,713,054.50.
Recent Trading Activity for Aclaris Therapeutics (NASDAQ:ACRS)
Shares of Aclaris Therapeutics closed the previous trading session at with 21.139699935913086 shares trading hands.